JP2005521705A - 化合物および方法 - Google Patents

化合物および方法 Download PDF

Info

Publication number
JP2005521705A
JP2005521705A JP2003579735A JP2003579735A JP2005521705A JP 2005521705 A JP2005521705 A JP 2005521705A JP 2003579735 A JP2003579735 A JP 2003579735A JP 2003579735 A JP2003579735 A JP 2003579735A JP 2005521705 A JP2005521705 A JP 2005521705A
Authority
JP
Japan
Prior art keywords
alkyl
amino
ethyl
het
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003579735A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005521705A5 (https=
Inventor
スコット・ケイ・トンプソン
ジェイムズ・エス・フラジー
ララ・エス・カランダー
マ・チュン
ジョゼフ・ピー・マリノ
マイケル・ジェイ・ニーブ
アジタ・バット
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of JP2005521705A publication Critical patent/JP2005521705A/ja
Publication of JP2005521705A5 publication Critical patent/JP2005521705A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
JP2003579735A 2002-03-27 2003-03-26 化合物および方法 Pending JP2005521705A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36841502P 2002-03-27 2002-03-27
PCT/US2003/009039 WO2003082192A2 (en) 2002-03-27 2003-03-26 Certain pharmaceutically useful substituted aminoalkyl heterocycles

Publications (2)

Publication Number Publication Date
JP2005521705A true JP2005521705A (ja) 2005-07-21
JP2005521705A5 JP2005521705A5 (https=) 2006-05-18

Family

ID=28675483

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003579735A Pending JP2005521705A (ja) 2002-03-27 2003-03-26 化合物および方法

Country Status (8)

Country Link
US (1) US7323494B2 (https=)
EP (1) EP1490047B1 (https=)
JP (1) JP2005521705A (https=)
AT (1) ATE453389T1 (https=)
AU (1) AU2003223340A1 (https=)
DE (1) DE60330758D1 (https=)
ES (1) ES2337037T3 (https=)
WO (1) WO2003082192A2 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004509161A (ja) * 2000-09-18 2004-03-25 グラクソ　グループ　リミテッド Ｌｘｒのアゴニストとして有用な置換アミノプロポキシアリール誘導体
AU2003226094A1 (en) 2002-03-27 2003-10-13 Smithkline Beecham Corporation Compounds and methods
EP1487776A4 (en) 2002-03-27 2005-05-25 Smithkline Beecham Corp ACID COMPOUNDS AND ESTERS AND METHODS OF USE THEREOF
US20050171084A1 (en) * 2002-03-27 2005-08-04 Cairns William J. Methods of treatment with lxr modulators
US7247748B2 (en) 2002-03-27 2007-07-24 Smithkline Corporation Amide compounds and methods of using the same
WO2004043457A1 (en) * 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
FR2869904B1 (fr) 2004-05-07 2006-07-28 Fournier S A Sa Lab Modulateurs des recepteurs lxr
IL166149A0 (en) * 2005-01-05 2006-01-15 Hadasit Med Res Service Use of ezetimibe and amiodarone in protection against beta-amyloid neurotoxicity
ES2380499T3 (es) 2006-11-30 2012-05-14 Kowa Company. Ltd. Compuesto de Carbinol sustituido
US7919509B2 (en) 2008-02-29 2011-04-05 Kowa Company, Ltd. 2-oxochromene derivatives
US7951822B2 (en) 2008-03-31 2011-05-31 Kowa Company, Ltd. 1,3-dihydroisobenzofuran derivatives
WO2009133692A1 (ja) 2008-04-30 2009-11-05 興和株式会社 キノリン化合物
JP5541803B2 (ja) 2008-05-29 2014-07-09 興和株式会社 環状リンカーを有する置換カルビノール化合物
CN102438991B (zh) 2009-04-29 2015-08-26 兴和株式会社 具有杂环连接基的甲醇化合物
US20130274212A1 (en) 2010-09-07 2013-10-17 Snu R&Db Foundation Sesterterpene Compounds and Use Thereof
CN110494415A (zh) 2017-03-03 2019-11-22 睿治尼斯公司 具有改善的稳定性的制剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533007A (ja) * 2002-03-27 2005-11-04 スミスクライン・ビーチャム・コーポレイション Ｌｘｒ調節因子を用いる治療方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3889545T2 (de) 1987-10-20 1994-10-13 Otsuka Pharma Co Ltd Phenylcarbonsäure-abkömmlinge.
US20030153541A1 (en) 1997-10-31 2003-08-14 Robert Dudley Novel anticholesterol compositions and method for using same
US6316503B1 (en) * 1999-03-15 2001-11-13 Tularik Inc. LXR modulators
AU2000235960A1 (en) 2000-02-14 2001-08-27 Tularik, Inc. Lxr modulators
JP2004509161A (ja) 2000-09-18 2004-03-25 グラクソ　グループ　リミテッド Ｌｘｒのアゴニストとして有用な置換アミノプロポキシアリール誘導体
US20030229062A1 (en) 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
JP2005511713A (ja) 2001-12-07 2005-04-28 ザ・リージェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア 加齢性黄斑変性についての処置
US7470659B2 (en) 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US7247748B2 (en) 2002-03-27 2007-07-24 Smithkline Corporation Amide compounds and methods of using the same
AU2003226094A1 (en) 2002-03-27 2003-10-13 Smithkline Beecham Corporation Compounds and methods
EP1487776A4 (en) 2002-03-27 2005-05-25 Smithkline Beecham Corp ACID COMPOUNDS AND ESTERS AND METHODS OF USE THEREOF
WO2004058175A2 (en) 2002-12-23 2004-07-15 Irm Llc Novel use of liver x receptor agonists
GB0230177D0 (en) 2002-12-24 2003-02-05 Karobio Ab LXR beta crystal
EP1635832A2 (en) 2003-06-06 2006-03-22 Merck & Co., Inc. Combination therapy for the treatment of diabetes
WO2004110368A2 (en) 2003-06-06 2004-12-23 Merck & Co., Inc. Combination therapy for the treatment of hypertension
US20060189693A1 (en) 2003-07-22 2006-08-24 Barone Frank C Methods of treatment with lxr agonists
EP1653938A2 (en) 2003-07-28 2006-05-10 Glaxo Group Limited Methods of treatment of inflammatory bowel disease with lxr agonists
WO2005055998A1 (en) 2003-12-04 2005-06-23 Smithkline Beecham Corporation Methods of treatment with lxr agonists
RU2006124843A (ru) 2003-12-12 2008-01-20 Уайт (Us) Хинолины, пригодные для лечения сердечно-сосудистого заболевания
EP1758651A2 (en) 2004-06-24 2007-03-07 Galapagos N.V. Lxr agonists to promote bone homeostasis
US20080255111A1 (en) 2004-07-02 2008-10-16 Sankyo Company Limited Tissue Factor Production Inhibitor

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005533007A (ja) * 2002-03-27 2005-11-04 スミスクライン・ビーチャム・コーポレイション Ｌｘｒ調節因子を用いる治療方法

Also Published As

Publication number Publication date
US7323494B2 (en) 2008-01-29
DE60330758D1 (de) 2010-02-11
WO2003082192A2 (en) 2003-10-09
WO2003082192A3 (en) 2003-12-18
AU2003223340A1 (en) 2003-10-13
AU2003223340A8 (en) 2003-10-13
ES2337037T3 (es) 2010-04-20
EP1490047A2 (en) 2004-12-29
EP1490047A4 (en) 2006-01-04
EP1490047B1 (en) 2009-12-30
US20050165045A1 (en) 2005-07-28
ATE453389T1 (de) 2010-01-15

Similar Documents

Publication Publication Date Title
JP4471842B2 (ja) アミド化合物および該化合物を用いる方法
AU2003218342B2 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7622594B2 (en) Glucocortioid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
JP2005521705A (ja) 化合物および方法
US6858627B2 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
EP1539141B1 (en) 3-(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases
JP2010047582A (ja) 酸およびエステル化合物ならびにその使用方法
US7741361B2 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US20040010148A1 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
FR2567885A1 (fr) Derives 3-aminopropoxyaryliques, leur preparation, leur application comme medicaments et compositions pharmaceutiques les contenant
JP2010043112A (ja) 化合物および方法
EP1467982A1 (en) Glucocorticoid mimetics, methods of making them, pharmaceutical formulations containing them, and uses thereof
JP7013446B2 (ja) Ｇａｂａ（ａ）受容体モジュレーター、及び、喘息における気道過敏及び炎症を抑制するための方法
JP2012102018A (ja) アミド化合物
WO2005023247A1 (en) Compounds and methods
WO2005023188A2 (en) Compounds and methods
WO2005023196A2 (en) Compounds and methods
JP2009507815A (ja) チアゾール化合物およびｐｇｄ２アンタゴニストとしてのその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090908

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091208

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100108

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100118

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100608

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101109